Literature DB >> 20712570

The dual role of tumor necrosis factor (TNF) in cancer biology.

Loris Bertazza1, Simone Mocellin.   

Abstract

Tumor necrosis factor (TNF) is a cytokine with well known anticancer properties and is being utilized as anticancer agent for the treatment of patients with locally advanced solid tumors. However, TNF role in cancer biology is debated. In fact, in spite of the wealth of evidence supporting its antitumor activity, the cascade of molecular events underlying TNF-mediated tumor regression observed in vivo is still incompletely elucidated. Furthermore, some preclinical findings suggest that TNF may even promote cancer development and progression. With this work we intend to summarize the molecular biology of TNF (with particular regard to its tumor-related activities) and review the experimental and clinical evidence currently available describing the complex and sometime apparently conflicting relationship between this cytokine, cancer biology and antitumor therapy. We also propose a model to explain the dual effect of TNF based on the exposure time and cytokine levels reached within the tumor microenvironment. Finally, we overview recent research findings that might lead to new ways for exploiting the anticancer potential of TNF in the clinical setting.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20712570     DOI: 10.2174/092986710793176339

Source DB:  PubMed          Journal:  Curr Med Chem        ISSN: 0929-8673            Impact factor:   4.530


  38 in total

Review 1.  Concordance of preclinical and clinical pharmacology and toxicology of monoclonal antibodies and fusion proteins: soluble targets.

Authors:  Pauline L Martin; Peter J Bugelski
Journal:  Br J Pharmacol       Date:  2012-06       Impact factor: 8.739

2.  Activities of multiple cancer-related pathways are associated with BRAF mutation and predict the resistance to BRAF/MEK inhibitors in melanoma cells.

Authors:  Dingxie Liu; Xuan Liu; Mingzhao Xing
Journal:  Cell Cycle       Date:  2013-10-29       Impact factor: 4.534

Review 3.  LPS Preconditioning Attenuates Apoptosis Mechanism by Inhibiting NF-κB and Caspase-3 Activity: TLR4 Pre-activation in the Signaling Pathway of LPS-Induced Neuroprotection.

Authors:  Pushpa Gandi Sangaran; Zaridatul Aini Ibrahim; Zamri Chik; Zahurin Mohamed; Abolhassan Ahmadiani
Journal:  Mol Neurobiol       Date:  2021-01-09       Impact factor: 5.590

Review 4.  Roles of cytotoxic and helper innate lymphoid cells in cancer.

Authors:  Camille Guillerey
Journal:  Mamm Genome       Date:  2018-09-03       Impact factor: 2.957

Review 5.  Gene therapy for brain tumors: basic developments and clinical implementation.

Authors:  Hikmat Assi; Marianela Candolfi; Gregory Baker; Yohei Mineharu; Pedro R Lowenstein; Maria G Castro
Journal:  Neurosci Lett       Date:  2012-08-10       Impact factor: 3.046

6.  Differential effects of cyclosporin and etanercept treatment on various pathologic parameters in a murine model of irradiation-induced mucositis.

Authors:  David Tung; Peter H Cheung; James Wilson; Gregory Tudor; Catherine Booth; Saurabh Saha
Journal:  Curr Ther Res Clin Exp       Date:  2012-09

Review 7.  Therapy-induced microenvironmental changes in cancer.

Authors:  Yuting Ma; Heng Yang; Jonathan M Pitt; Guido Kroemer; Laurence Zitvogel
Journal:  J Mol Med (Berl)       Date:  2016-03-02       Impact factor: 4.599

8.  Molecular correlates and prognostic value of tmTNF-α expression in colorectal cancer of 5-Fluorouracil-Based Adjuvant Therapy.

Authors:  Xiaogai Li; Shihai Wang; HuiJun Ren; Junfen Ma; Xiaoxu Sun; Nan Li; Cailin Liu; Kaida Huang; Min Xu; Liang Ming
Journal:  Cancer Biol Ther       Date:  2016-06-02       Impact factor: 4.742

9.  Losses of cytokines and chemokines are common genetic features of human cancers: the somatic copy number alterations are correlated with patient prognoses and therapeutic resistance.

Authors:  Henry Sung-Ching Wong; Wei-Chiao Chang
Journal:  Oncoimmunology       Date:  2018-07-30       Impact factor: 8.110

Review 10.  A multi-targeted approach to suppress tumor-promoting inflammation.

Authors:  Abbas K Samadi; Alan Bilsland; Alexandros G Georgakilas; Amedeo Amedei; Amr Amin; Anupam Bishayee; Asfar S Azmi; Bal L Lokeshwar; Brendan Grue; Carolina Panis; Chandra S Boosani; Deepak Poudyal; Diana M Stafforini; Dipita Bhakta; Elena Niccolai; Gunjan Guha; H P Vasantha Rupasinghe; Hiromasa Fujii; Kanya Honoki; Kapil Mehta; Katia Aquilano; Leroy Lowe; Lorne J Hofseth; Luigi Ricciardiello; Maria Rosa Ciriolo; Neetu Singh; Richard L Whelan; Rupesh Chaturvedi; S Salman Ashraf; H M C Shantha Kumara; Somaira Nowsheen; Sulma I Mohammed; W Nicol Keith; William G Helferich; Xujuan Yang
Journal:  Semin Cancer Biol       Date:  2015-05-05       Impact factor: 15.707

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.